Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Gastritis III: Clinical Manifestations and Management

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

Gastritis II: Pathophysiology

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...

Gastritis-II: Pathophysiology

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

Esophageal Strictures-II: Clinical Features and Management

Esophageal Strictures-II: Clinical Features and Management

Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Diagnosis and treatment of ANCA-associated vasculitis : S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for ENT Medicine and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German Radiological Society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German Rheumatism League Federal Association e. V.]

Zeitschrift fur Rheumatologie·2025

Same author

[Diagnosis and treatment of ANCA-associated vasculitis : SHORT VERSION of the S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for Otorhinolaryngology and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German Radiological Society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German Rheumatism League Federal Association e. V.]

Zeitschrift fur Rheumatologie·2025

Same author

[Cortisone-free rheumatology-Distant vision or clinical routine soon?]

Zeitschrift fur Rheumatologie·2021

Same author

[S2k guidelines: management of large-vessel vasculitis].

Zeitschrift fur Rheumatologie·2020

Same author

[S2k guidelines (executive summary): management of large-vessel vasculitis].

Zeitschrift fur Rheumatologie·2020

Same author

[Treatment of giant cell arteritis: what is in the pipeline?]

Zeitschrift fur Rheumatologie·2020

Same journal

[Prevention strategies in rheumatoid arthritis : From primary prevention to targeted drug interception].

Zeitschrift fur Rheumatologie·2026

Same journal

Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab.

Zeitschrift fur Rheumatologie·2026

Same journal

Evaluating the comparative efficacy of belimumab vs. anifrolumab in systemic lupus erythematosus: a response.

Zeitschrift fur Rheumatologie·2026

Same journal

[Update: DMARDs for MGUS].

Zeitschrift fur Rheumatologie·2026

Same journal

[A potpourri of diagnoses-Unusual manifestations of a chronic inflammatory bowel disease : Case report].

Zeitschrift fur Rheumatologie·2026

Same journal

[Not measurable but immeasurably important : Fever-The leading symptom of ancient medical theory].

Zeitschrift fur Rheumatologie·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 22, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

[Esophagitis during immunosuppression].

F Moosig¹, W L Gross

¹Poliklinik für Rheumatologie, Universität zu Lübeck und Klinikum Bad Bramstedt, Oskar-Alexander-Str. 26, 24576, Bad Bramstedt, Deutschland. f.moosig@klinikumbb.de

Zeitschrift Fur Rheumatologie

|May 5, 2012

Summary

This summary is machine-generated.

Cytomegalovirus (CMV) esophagitis, typically seen in AIDS patients, can occur in non-HIV individuals due to immunosuppressive therapy. Careful monitoring and adjusted medication are vital to prevent complications from long-term glucocorticoid use.

More Related Videos

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation

Published on: March 15, 2020

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

Published on: February 10, 2017

Related Experiment Videos

Last Updated: May 22, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis

Published on: May 10, 2024

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation

Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation

Published on: March 15, 2020

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

ADSC-sheet Transplantation to Prevent Stricture after Extended Esophageal Endoscopic Submucosal Dissection

Published on: February 10, 2017

Area of Science:

Gastroenterology and Infectious Diseases
Immunology and Rheumatology

Background:

Cytomegalovirus (CMV) esophagitis is predominantly documented in individuals with acquired immunodeficiency syndrome (AIDS).
Characteristic endoscopic findings include distal and hemorrhagic ulcerations of the esophagus.

Observation:

CMV esophagitis can manifest in non-human immunodeficiency virus (HIV)-infected patients as a consequence of immunosuppressive treatment.
A presented case involved excessive long-term prednisolone dosage leading to CMV esophagitis.
Published cases of CMV esophagitis in rheumatic diseases consistently involved high-dose glucocorticoid therapy.

Findings:

Excessive and prolonged glucocorticoid use, such as high-dose prednisolone, is a risk factor for CMV esophagitis.
Rheumatic disease patients on glucocorticoids are particularly susceptible to this opportunistic infection.

Implications:

Regular rheumatological screening and judicious adjustment of immunosuppressive therapy are crucial.
Maintaining disease control with minimized glucocorticoid dosage is essential for preventing CMV esophagitis.
This highlights the importance of balancing immunosuppression for rheumatic conditions with the risk of opportunistic infections.